Is Aducanumab for LMICs? Promises and Challenges

Is Aducanumab for LMICs? Promises and Challenges

Aducanumab, a human monoclonal antibody, was approved in June of 2021 as the first disease-modifying treatment for Alzheimer’s disease by the United States Food and Drug Administration (U.S. FDA). A substantial proportion of patients with Alzheimer’s disease live in low- and middle-income countries...

Full description

Bibliographic Details
Main Authors: Illangage P. C. Gunawardena, Thaarvena Retinasamy, Mohd. Farooq Shaikh
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:Brain Sciences
Subjects:
Alzheimer’s disease
aducanumab
LMICs
APOE
burden of disease
treatment cost
Online Access:https://www.mdpi.com/2076-3425/11/11/1547

Similar Items

Similar Items